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Introduction: Parkinsonism occurs in all ethnic groups worldwide; however, there are wide 
variations in the prevalence rates reported from different countries, even for neighboring 
regions. The huge socioeconomic burden of parkinsonism necessitates the need for prevalence 
studies in each country. So far, there is neither data registry nor prevalence information on 
parkinsonism in the Iranian population. The aim of our study was to estimate the prevalence 
rate of probable parkinsonism in a huge urban area in Iran, Tehran using a community-based 
door-to-door survey.
Materials and methods: We used a random multistage sampling of the households within 
the network of health centers consisting of 374 subunits in all 22 districts throughout the 
entire urban area of Tehran. Overall, 20,621 individuals answered the baseline checklist 
and screening questionnaire and data from 19,500 persons aged 30 years were entered in 
the final analysis. Health care professionals used a new six-item screening questionnaire for 
parkinsonism, which has been previously shown to have a high validity and diagnostic value 
in the same population.
Results: A total of 157 cases were screened for parkinsonism using the validated six-item 
questionnaire. After age and sex adjustment based on the Tehran population, the prevalence of 
parkinsonism was calculated as 222.9 per 100,000. Using the World Health Organization’s World 
Standard Population, the standardized prevalence rate of parkinsonism was 285 per 100,000 (95% 
confidence interval 240–329). The male:female ratio of probable parkinsonism was calculated 
as 1.62, and there was a significant increase in the screening rate by advancing age.
Conclusion: The calculated rates for the prevalence of parkinsonism in our study are closer 
to reports from some European and Middle Eastern countries, higher than reports from Eastern 
Asian and African populations, and lower than Australia. The prevalence rate of 200 in 100,000 
for parkinsonism in Tehran, Iran could be considered a medium-to-high rate.
Keywords: parkinsonism, Parkinson’s disease, prevalence, door-to-door survey, population-
based
Introduction
Parkinsonism is the second-most common neurodegenerative disorder, with extremely 
high psychosocial impacts and noticeable declines in patients’ quality of life. Idiopathic 
Parkinson’s disease (IPD), also named PD, is the most prevalent type of parkinsonism; 
however, about 30%–40% of patients suffer from other types, generally called atypical 
parkinsonism.1,2 Although these conditions overlap in symptoms, different underlying 
pathologies are involved.
PD incidence and prevalence increase with age,3 which makes it an impending 
public health issue in rapidly aging societies, especially less developed countries that 
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might not be well equipped to encounter the high burden of 
geriatric neurodegenerative disorders. Although a number 
of studies have been performed on the prevalence of par-
kinsonism, current data are mainly limited to developed 
countries or rather smaller communities where data regis-
tries are practically available in their health care systems.4–8 
Previous studies have demonstrated considerable variety in 
their estimations, probably in part due to methodological 
issues, in addition to environmental and ethnodemographic 
determinants, such as the age and ethnic groups of the study 
population.9 For instance, the crude prevalence of PD has 
been estimated to be as low as 15 per 100,000 individuals in 
the People’s Republic of China (PRC)10 to as high as 800 per 
100,000 persons in Albania.11 This large variation highlights 
the fact that epidemiologic features of parkinsonism cannot 
be generalized to all ethnic groups and societies. Furthermore, 
the method of data collection is another crucial determinant 
that might lead to either under- or overestimation of PD 
prevalence. While electronic central registries are available in 
many developed countries, door-to-door surveys are the most 
common method of data collection in neuroepidemiologic 
studies in poor-resource developing countries. Nevertheless, 
door-to-door studies have been shown to have the advantage 
of fewer underdiagnosed cases.12
With 78.4 million inhabitants, Iran is the world’s 17th-
most populous country, and is experiencing a rapidly aging 
demographic shift.13 The growing trend of aging in Iran 
has been shown in national censuses where the propor-
tion of those 60 years of age increased 1% from 2006 
to 2011,14,15 and will reach 10.5% in 2025 and as high as 
21.7% in 2050.15,16 However, there is a dearth of information 
about epidemiological features of PD not only in the Iranian 
population, but also in the greater Eastern Mediterranean 
World Health Organization (WHO) region, where different 
populations with specific environmental and ethnogenetic 
properties live. Data from Arabic countries in the Middle 
East are also absent, except for recent surveys in Jordan17 
and Egypt18 showing prevalence rates of 58.8 and 452.1 per 
100,000, respectively, which demonstrates a wide range of 
variation.
Currently, there is a lack of evidence on the epidemio-
logic features of parkinsonism in the Iranian population, and 
even the number of movement-disorder specialists is unclear 
in Iran,19 which raises potential obstacles and concerns for 
future health policy making in a country with a rapidly aging 
population at risk of neurodegenerative diseases, such as PD. 
Therefore, the aim of this study was to estimate the preva-
lence rate of probable parkinsonism in a huge urban area 
of Tehran, Iran. Having no access to any registered data on 
PD, we designed a door-to-door community-based method 
for data collection using a previously validated screening 
instrument with high diagnostic values.20
Materials and methods
study setting
This community-based door-to-door study was performed 
in Tehran, Iran. Tehran, the capital city of Iran and the 
largest metropolitan area in West Asia, has a population 
of 8,300,000 inhabitants, and surpasses 14,000,000 in the 
wider metropolitan area13 with 22 urban districts, according 
to the latest estimations. The present work is part of a com-
prehensive project designed to study the epidemiology of 
major neurological disorders, namely stroke, PD, epilepsy, 
peripheral neuropathy, restless leg syndrome, and headache, 
in the adult population of Tehran. The prevalence-date points 
were during October 2011 and January 2012.
ethical considerations
The study protocol was approved by the ethics committee 
of the Firoozgar Clinical Research Development Center 
(FCRDC) (affiliated with Iran University of Medical Sci-
ences) in Tehran, Iran (MT.140, approved in June 2011). 
Each participant was informed about the aims and objectives 
of the study before participation, and they were free to with-
draw from the survey whenever they wanted. Furthermore, 
the identity of research participants was protected, since the 
data files were anonymous.
sample-size calculation and sampling 
method
With regard to a prevalence rate of 257 per 100,000 indi-
viduals, which was estimated in a door-to-door survey in 
Caucasians21 and an effect size of seven per 100,000 with 
the assumption of 0.05 for type I (α) error in the estima-
tion, the total required sample size was calculated as 16,000 
individuals using the following formula (where P represents 
the estimated prevalence rate and d shows the effect size of 
the estimation):
N
Z P
d
=
× −
=
−
α
2
2
2 3 3
5 2
1 1 96 2 57 10 1 2 57 10
7 10
( ) . [ . ( ( . ))]
( )
P × × − ×
×
− −
 
 (1)
As Tehran comprises 22 hierarchical districts with regard 
to socioeconomic status, it is of utmost importance to cover 
all regions in any epidemiologic study targeting the city’s 
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population. As a result, we used a probability multistage-
sampling method covering all urban districts of Tehran. For 
this purpose, each of the 22 districts was considered one 
sampling stratum, each of which consists of several blocks 
and households as the clusters. Throughout the Tehran urban 
area, there is a network of health centers, with a total of 
374 subunits covering all districts, which are organized by 
the health deputy of Tehran municipality. Each of the health 
centers is responsible for a determined number of residing 
blocks and households that are coded by unique numbers. 
With regard to the stratified proportional sample size for each 
district and their subunits where one single health center is 
located, random cluster sampling was used to recruit the 
needed number of households to fulfill the calculated sample 
size for each subunit.
screening tool
The study checklist consisted of three main sections: baseline 
information (ie, age, sex, and educational, marital, and work-
ing status), comorbidity profile, and screening questions. In 
this study, we used our previously validated screening ques-
tionnaire for parkinsonism.20 As a brief description, after all 
screening questions on different symptoms of parkinsonism 
from several previously used instruments in neuroepidemio-
logic surveys were merged, a new combination of six items 
was constructed. These items included “stiffness and rigid-
ity in legs”, “tremor and shaking”, “slower daily activity”, 
“troublesome buttoning”, “troublesome arm swing”, and 
“feet stuck to floor”. This novel six-item tool has been shown 
to have 97% accuracy, 90% sensitivity, and 96% specificity 
to screen parkinsonism in a similar Iranian population but 
with different participants.20 Individuals with parkinsonism 
were screened if they answered positively to all of these 
six questions. In addition, we also included unique items 
on symptoms of parkinsonism from other screening tools, 
namely the Sicilian Neuro-Epidemiology Study (SNES; five 
screening questions),22 the revised 2009 version of the WHO 
screening instrument to measure the prevalence of neuro-
logical disability in resource-poor settings (seven screening 
questions),23 and the questionnaire developed by Tanner 
et al (nine screening questions).24,25 The aforementioned 
four questionnaires consist of some other items on physical 
examination; however, in accordance with the scope of our 
study, we included only those primary screening items that 
could be asked of people. Therefore, we were able to estimate 
and compare the prevalence rate of suspicious parkinsonism 
based on different screening tools. The full list of combined 
screening questionnaires that we used in our study has been 
previously published,20 which can be retrieved in case of 
interest or need.
Data collection
Data collection was done through face-to-face interviews 
with the participants. Surveyors were among the health care 
workers who were employed in the health centers of each dis-
trict of Tehran, and were trained to conduct the study through 
a 1-day workshop that was held in September 2011. Each of 
the surveyors was responsible for a number of households 
throughout their district and subunit region. All members of 
each presented household were asked to participate in the 
survey if they were aged 30 years. After the introduction of 
the survey and study aims, the checklist consisting of screen-
ing items for parkinsonism was filled by the surveyors for 
each eligible family member. In overall 20,621 individuals 
answered the baseline checklist and screening questionnaire; 
however, with regard to missing values and data cleaning, 
information from a total number of 19,500 persons was 
entered in the final analysis, resulting in a 94.6% rate for 
valid participation.
statistical analysis
Data were analyzed using SPSS version 20 (IBM, Armonk, 
NY, USA) and Microsoft Excel 2010 software. To describe 
quantitative and nominal/categorical variables, mean (stan-
dard deviation [SD]) and frequency percentages are reported, 
respectively. In order to calculate the 95% confidence inter-
vals (CIs) for the prevalence rates, the standard error (SE) of 
estimation was calculated using following formula (where P 
is the point prevalence rate and N is the total sample size):
 SE = −P
N
( )1 P
 (2)
Using the latest accessible data for the age and sex dis-
tribution of the Tehran population (Table S1) based on the 
national census in 2008, prevalence rates were adjusted. In 
the next step, we used the WHO World Standard Population 
to readjust the prevalence rates to be able to compare the 
prevalence rates of our study with other reports from different 
countries. The WHO World Standard Population is a unique 
standard age- and sex-specific distribution for a hypothetical 
population that is recommended by different studies to use the 
same reference-population pyramid to adjust their findings 
for. This method enables us to easily compare prevalence 
features between studies with various population pyramids 
with dissimilar age and sex distributions. In order to analyze 
the increasing pattern of the prevalence rate of parkinsonism 
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by aging, three regression models were performed, consisting 
of linear, quadratic, and cubic equations, to find the best-fitted 
model based on the R2 value. The null hypothesis behind these 
regression models is that by one increase in the age-group 
of the study population, the prevalence rate of parkinsonism 
increases by either one, two, or three times.
Results
Baseline characteristics
In total, 12,907 (66.2%) women and 6,593 (33.8%) men 
participated in this survey. The mean age of the entire study 
population was 56.5 (SD 10.2) years, ranging between 
30 and 95 years. Figure 1 shows the population pyramid 
of the participants regarding their age-group and sex. Less 
than a fifth (17.2%, n=3,266) of the study population were 
illiterate, and the majority of them (81.8%, n=15,147) were 
married. Based on the self-reported checklist, hypertension 
(29.9%, n=5,838), osteoarthritis (18.0%, n=3,519), and 
diabetes (18.0%, n=3,516) were the most common comor-
bidities. A complete list of sociodemographic and baseline 
characteristics of the participants is shown in Table 1.
crude prevalence rates
On the self-reported questionnaire, 142 individuals men-
tioned a history of parkinsonism, which resulted in a crude 
prevalence rate of 728.2 per 100,000 (95% CI 620–860). 
Using the new six-item screening instrument validated in 
our previous study, 157 participants were screened as cases 
suspicious for parkinsonism (crude rate 805.1 per 100,000, 
95% CI 690–940). The mean age of the positively screened 
cases was 64.5 (SD 10.9) years, ranging between 39 and 
89 years, and only 21 (13.4%) individuals were younger than 
50 years. With regard to symptoms related to parkinsonism, 
cardinal features, namely tremor, bradykinesia, and rigid-
ity, were seen in all of the screened cases. Stooped posture 
(91.5%), impaired balance (89.5%), gait disorders (87%), 
inexpressive face (75.3%), smelling problems (65.1%), and 
softer voice (64.4%) were also commonly observed among 
the positively screened individuals. Table 2 summarizes the 
crude numbers and prevalence rate of screened cases in each 
age-group and in the total study population using different 
screening instruments. The highest crude prevalence rate was 
estimated by the SNES items, where 174 cases were screened 
(crude rate 892.3 per 100,000, 95% CI 770–1,030). The 
crude prevalence rate of suspicious parkinsonism using the 
new six-item screening instrument in different age-groups is 
illustrated separately for males, females, and the total study 
population in Table 2. As shown, the crude prevalence rate 
was 1% in younger groups aged 65 years. While the 
crude prevalence rate of screened parkinsonism decreased 
from 4.6% in the age-group 80–84 years to 1.7% among 
those who aged 85 years, there was a steady increase in 
the prevalence rate of parkinsonism in females up to 5.9% 
in the age-group 85 years.
age- and sex-adjusted prevalence rates
With regard to the skewed age distribution and uneven 
sex ratio of the study population, the first adjustment was 
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Figure 1 Population pyramid of the study participants (n=19,500), showing the number of males and females in each age category.
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Table 1 sociodemographic and baseline characteristics of the 
study population (n=19,500)
Characteristics Value
Age, years
Mean (sD) 56.5 (10.2)
Sex, n (%)
Female
Male
12,907 (66.2)
6,593 (33.8)
Level of education, n (%)
illiterate
Primary school
secondary school
high school/diploma
college/university
Missing values
3,266 (17.2)
5,344 (28.1)
3,365 (17.7)
4,781 (25.1)
2,267 (11.9)
477
Marital status, n (%)
single
Married
Widowed
Divorced
Missing values
316 (1.7)
15,147 (81.8)
2,703 (14.6)
354 (1.9)
980
Comorbidities, n (%)
heart failure
hypertension
Osteoarthritis
Diabetes
stroke
cancers
2,657 (13.6)
5,838 (29.9)
3,519 (18.0)
3,516 (18.0)
431 (2.2)
199 (1.0)
Working status, n (%)
Unemployed
employed
Paid without working
housekeeper
retired
Others
Missing values
570 (3.2)
2,831 (15.9)
324 (1.8)
9,584 (53.8)
3,989 (22.4)
520 (2.9)
1,682
Abbreviation: sD, standard deviation.
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performed using the population features of the Tehran urban 
area obtained from the national census in 2008 (Table 3). 
After age and sex adjustment, the prevalence of screened 
parkinsonian cases was estimated as 222.9 per 100,000 (95% 
CI 160–300) based on the new six-item screening instrument. 
As shown in Table 3, the highest and lowest prevalence rates 
were estimated by the SNES (adjusted rate 234.4 per 100,000, 
95% CI 180–310) and Tanner et al’s (adjusted rate 82.7 per 
100,000, 95% CI 50–130) instruments, respectively. Figure 2 
illustrates the sex-specific age-adjusted prevalence rate of 
suspicious parkinsonism using the new validated instrument 
in different age categories of the study population based on 
the Tehran census population. After age adjustment, a steady 
increase was seen in the prevalence rate of parkinsonism 
by increasing age, which was accelerated after 65 years of 
age. As illustrated in Figure 3, a cubic regression (adjusted 
R2=0.962, P-value for trend 0.026) showed the best-fitted 
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model for trend analysis of the increasing prevalence rate of 
parkinsonism by advancing age compared to linear (adjusted 
R2=0.764, P-value for trend 0.001) and quadratic (adjusted 
R2=0.920, P-value for trend 0.005) models. This shows that 
with each 5-year increase in age, the prevalence of parkin-
sonism is more likely to increase to the power of three. The 
male:female ratio for the overall prevalence of parkinsonism 
was calculated as 1.62 based on the results from the new 
validated instrument. Table 3 also shows prevalence rates of 
screened parkinsonism using different screening instruments 
in each age category and in total adjusted for age and sex 
based on the WHO World Standard Population. The overall 
adjusted prevalence rate based on the new six-item instrument 
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Figure 2 Sex-specific age-adjusted prevalence rate of suspicious parkinsonism using 
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increased to 284.9 per 100,000 (95% CI 240–330) adjusting 
for the WHO World Standard Population. Moreover, the 
SNES estimation of parkinsonism also increased to 296.0 per 
100,000 (95% CI 250–342) after the second adjustment.
Discussion
Main findings
Our investigation is the first community-based door-to-door 
prevalence study of parkinsonism in Iran, in which 19,500 
individuals were screened using a validated novel instrument. 
Although our study lacked Phase II confirmatory investiga-
tion by neurologists, it benefited from a validated novel 
screening questionnaire that has been previously shown to 
have high diagnostic value for screening of parkinsonism in 
the same community.20 Based on our validated instrument20 
and after adjustment for the age and sex distribution of the 
Tehran population, the prevalence rate of parkinsonism was 
found to be 223 per 100,000, which increased to 285 per 
100,000 following adjustment for the WHO World Standard 
Population, both of which could be considered high rates.
Prevalence of parkinsonism
A literature review on the prevalence rate of parkinsonism and 
PD confirms that the results vary widely in different ethnic 
groups and countries. Morgante et al reported a prevalence of 
323.4 per 100,000 for all types of parkinsonism among people 
aged 40 years and over in the Aeolian Archipelago in Sicily, 
Italy.26 Also, Hobson et al in their record-based study, which 
was conducted in a rural area in north Wales, UK, found a 
prevalence of 122 per 100,000 for parkinsonism.27 Other 
reports on the prevalence of parkinsonism show quite a wide 
range: from 339.6 per 100,000 in Colombia28 to as high as 
659 per 100,000 in Egypt29 and 800 per 100,000 in Albania.11 
In another study on 15,482 Egyptians aged 40 years, 
the prevalence of parkinsonism was found to be 316.5 per 
100,000 people.30 Other neuroepidemiologic studies on 
parkinsonism have mainly focused on the prevalence and/or 
incidence of PD, which is the most common cause of 
parkinsonism.
Prevalence of Parkinson’s disease
Previous surveys have demonstrated that around 58%–70% 
of screened cases with parkinsonism actually suffer from 
IPD.1,2,30–33 Accordingly, it could be expected that PD preva-
lence in the Tehran population varies between 129–156 per 
100,000 (standardized by the Tehran population) or 165–199 
per 100,000 (standardized by the WHO World Standard 
Population). This rate lies in the wide range of PD prevalence 
that has been estimated from Caucasian populations, varying 
from 65 to 257 per 100,000.9 In a systematic review on the 
prevalence of PD in Asia conducted by Muangpaisan et al 
studies published from 1965 to 2008 were reviewed, and 
an age-standardized prevalence of 51.3–176.9 per 100,000 
in population-based door-to-door surveys was reported.34 
However, PD prevalence estimated from record-based 
studies ranged from 35.8 to 68.3 per 100,000 in the same 
geographic regions.34
Although it has been generally thought that PD is less com-
mon in Afro-Americans, Japanese, and some other Asians,9 the 
diversity in estimations can be also attributed to methodologi-
cal differences in addition to genetic and environmental factors. 
Population-based studies, such as door-to-door surveys like 
the current investigation, tend to overestimate PD prevalence, 
whereas record-based reports are based on only diagnosed 
cases and would definitely underestimate the real prevalence 
rates. Figure 4 summarizes the results from several prevalence 
studies reporting a global standardized (either WHO, US, or 
Europe standard reference populations) prevalence rate of 
PD in different countries located in the six WHO regions. 
Having standardized for a common hypothetical population, 
one can compare these prevalence features, even though they 
come from countries with huge differences in their population 
pyramids. Among these globally standardized rates, the highest 
and lowest prevalence has been shown in Australia (439.4 per 
100,000)35 and the PRC (16.7 per 100,000),10 respectively. Our 
WHO population-standardized estimation for Iran lies in the 
middle-to-high range. Figure 5 shows findings from reported 
local standardized prevalence rates using their own national 
population demography for adjustments; therefore, these find-
ings are affected by the age and sex distribution of the adult 
population in each country. However, PD prevalence has been 
reported to range between ten per 100,000 in all age-groups 
in Nigeria36 and 713 per 100,000 in inhabitants older than 
65 years in Germany.37 In general, population-based studies 
have resulted in rather higher PD prevalence rates compared 
to record-based registries in most regions (Figures 4 and 5). 
Moreover, among population-based studies prevalence of PD 
is commonly higher in European and Eastern Mediterranean 
regions compared to the African region. When focus is directed 
more on the Eastern Mediterranean, where Iran is located, a 
higher PD prevalence is seen in Egypt30 and Tunisia,38 Iran 
is in the middle range, and Saudi Arabia39 has the lowest 
estimation (Figure 5). Nonetheless, not only the differences 
in ethnicity but also various environmental factors may play 
a role in such varied prevalence features for PD. In the PRC, 
a tenfold difference has been shown in the prevalence of PD 
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Figure 4 global standardized prevalence rate of Parkinson’s disease using different data-collection methods in different countries from each of the six World health 
Organization regions.
Note: The star shows our own estimation from iran.
Abbreviation: Prc, People’s republic of china.
estimated from a nationwide survey covering different parts 
of the country.10
sex- and age-related prevalence features
Our findings showed a steady increase in the prevalence 
rate of parkinsonism by advancing age, with a male pre-
ponderance in all age-groups, which is in line with previous 
reports.40,41 Similarly, we also showed that a sudden rise in the 
incidence of parkinsonism happens after the age of 65 years, 
where the number of positively screened cases increased 
dramatically in a cubic function. Although Iran is known to 
be a country with rather a high consanguinity rate (37.4%),42 
which might have led to a higher relative prevalence of early 
onset parkinsonism, our findings showed that the mean age 
of positively screened cases and the proportion of those 
younger than 50 years were both similar to other populations. 
A higher prevalence of both PD and other parkinsonism in 
males has been repeatedly shown.40 Quite similar to our study, 
which showed a male:female ratio of 1.62 for the overall 
prevalence of parkinsonism, in a Norwegian survey on the 
incidence of PD, the overall age-standardized male:female 
ratio was 1.58.43 Although some studies have attributed the 
lower incidence and delayed onset of parkinsonism in females 
to hormonal factors, such as estrogens,43,44 a satisfactory 
explanation is still needed.
limitations and strengths
We acknowledge our study’s limitations, including the 
lack of Phase II confirmatory assessment by well-trained 
neurologists to exclude any secondary reason for the 
symptoms, which occurred due to the limited resources we 
had. However, the positively screened cases in our study 
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Figure 5 local/national standardized prevalence rate of Parkinson’s disease using different data-collection methods in different countries from each of the six World health 
Organization regions.
Note: The star shows our own estimation from iran.
could be considered as suspicious parkinsonism but not 
confirmed. The use of a novel six-item screening tool that 
has been shown to be a highly valid questionnaire with high 
diagnostic value in the same population20 is one strength to 
compensate this issue. Nonetheless, all other used screening 
instruments were confirmed in several studies, whereas our 
newly developed screening tool was validated in one study20 
and not yet confirmed by other different surveys. Therefore, 
the confirmatory phase could not only support more valid 
findings on the prevalence of parkinsonism but also confirm 
the six-item screening instrument in a large cohort, which 
could be considered for future research in this area.
Having used an acceptable sampling method in a huge 
urban area, our study is also the first attempt to investigate 
the prevalence of suspicious parkinsonism in the Iranian 
 population. However, since we did not recruit from rural areas, 
our findings should be generalized mainly for urban inhabitants 
and not the whole Iranian population. Furthermore, the door-
to-door sampling was performed mainly during the daytime, 
when most of the housewives are at home and most of the men 
are away. This might have induced the unequal sex distribution 
in our study population. The selected cutoff for age as 30 years 
was also based on previous studies41 and the rationale for the 
onset age of parkinsonism. Although adjusted for real Tehran 
and WHO-standardized populations, these two issues created 
age and sex skewness in our recruited study population, which 
must be considered when extrapolating the findings. Finally, it 
should be noted that the Tehran population could be a mixture 
of different ethnic groups, such as Persian, Azeri, and Kurd-
ish, and even immigrant subpopulations, mainly Afghans and 
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Iraqis. Therefore, our findings more appropriately refer to 
the Iranian population as a geographic entity rather than the 
Persian ethnic group, although they might be the major ethnic 
group in the Tehran urban area.
Conclusion
The calculated rates for the prevalence of parkinsonism in 
our study are closer to the reports from some European and 
Eastern Mediterranean regions, higher than the estimations 
from East Asian and African populations, and lower than 
Australia. The prevalence rate of 200 per 100,000 for 
parkinsonism in Tehran, Iran could be considered medium 
to high, and was estimated for an urban population from a 
metropolitan area, reflecting the possible high risk of expo-
sure to pollutants and other risk factors of urbanization.
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Table S1 age and sex distribution of Tehran population in 2008 (data from national census)
Age-group (years) Male Female Total
30 2,097,402 2,005,204 4,102,606
30–34 340,033 323,189 663,222
35–39 323,596 308,614 632,210
40–44 284,518 278,637 563,155
45–49 242,200 242,581 484,781
50–54 201,377 193,046 394,423
55–59 146,004 138,206 284,210
60–64 111,524 103,114 214,638
65–69 86,856 78,324 165,180
70–74 72,204 64,186 136,390
75 80,705 82,363 163,068
Total 3,986,419 3,817,464 7,803,883
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